Parkinson’s Disease Treatment Market
Parkinson’s Disease Treatment Market - Global Industry Assessment & Forecast
#
Pages:
215
Base Year:
2024
Dec - 2024
Format:
Report Code:
VMR-3923
Segments Covered
By
Drug Class Carbidopa-levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT inhibitors, Anticholinergics, Others
-
By
Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2024 |
| Forecast
Years:
|
2025 - 2035 |
 Historical
Years:
|
2019 - 2023 |
 Revenue
2024: |
USD 6.67 Billion |
 Revenue 2035:
|
USD 19.24 Billion |
 Revenue CAGR
(2025 - 2035): |
10.1% |
Fastest Growing Region (2025 -
2035)
|
Asia Pacific |
Largest Region (2024):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Parkinson’s Disease Treatment Market Segment Analysis
- Parkinson’s Disease Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Parkinson’s Disease Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
-
North America Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S.
- U.S. Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- U.S. Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S. Parkinson’s Disease Treatment Market, by Drug Class
- Canada
- Canada Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Canada Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Canada Parkinson’s Disease Treatment Market, by Drug Class
-
Mexico
- Mexico Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Mexico Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Mexico Parkinson’s Disease Treatment Market, by Drug Class
-
North America Parkinson’s Disease Treatment Market, by Drug Class
- Europe
-
Europe Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
-
Europe Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U. K.
- U.K. Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- U.K. Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.K. Parkinson’s Disease Treatment Market, by Drug Class
- France
- France Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- France Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- France Parkinson’s Disease Treatment Market, by Drug Class
-
Germany
- Germany Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Germany Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Parkinson’s Disease Treatment Market, by Drug Class
-
Italy
- Italy Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Italy Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Italy Parkinson’s Disease Treatment Market, by Drug Class
-
Spain
- Spain Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Spain Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Spain Parkinson’s Disease Treatment Market, by Drug Class
-
Rest of Europe
- Rest of Europe Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Rest of Europe Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Europe Parkinson’s Disease Treatment Market, by Drug Class
-
Europe Parkinson’s Disease Treatment Market, by Drug Class
- Asia Pacific
-
Asia Pacific Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
-
Asia Pacific Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China
- China Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- China Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China Parkinson’s Disease Treatment Market, by Drug Class
- Japan
- Japan Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Japan Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Japan Parkinson’s Disease Treatment Market, by Drug Class
-
Germany
- Germany Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Germany Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Parkinson’s Disease Treatment Market, by Drug Class
-
India
- India Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- India Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- India Parkinson’s Disease Treatment Market, by Drug Class
-
South Korea
- South Korea Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- South Korea Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Korea Parkinson’s Disease Treatment Market, by Drug Class
-
South East Asia
- South East Asia Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- South East Asia Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South East Asia Parkinson’s Disease Treatment Market, by Drug Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Rest of Asia Pacific Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Asia Pacific Parkinson’s Disease Treatment Market, by Drug Class
-
Asia Pacific Parkinson’s Disease Treatment Market, by Drug Class
- Latin America
-
Latin America Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
-
Latin America Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil
- Brazil Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Brazil Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil Parkinson’s Disease Treatment Market, by Drug Class
- Argentina
- Argentina Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Argentina Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Argentina Parkinson’s Disease Treatment Market, by Drug Class
-
Rest of Latin America
- Rest of Latin America Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Rest of Latin America Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Latin America Parkinson’s Disease Treatment Market, by Drug Class
-
Latin America Parkinson’s Disease Treatment Market, by Drug Class
- Middle East & Africa
-
Middle East & Africa Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
-
Middle East & Africa Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries
- GCC Countries Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- GCC Countries Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries Parkinson’s Disease Treatment Market, by Drug Class
- South Africa
- South Africa Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- South Africa Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Africa Parkinson’s Disease Treatment Market, by Drug Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Parkinson’s Disease Treatment Market, by Drug Class
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
- Rest of Middle East & Africa Parkinson’s Disease Treatment Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Middle East & Africa Parkinson’s Disease Treatment Market, by Drug Class
-
Middle East & Africa Parkinson’s Disease Treatment Market, by Drug Class
- North America
Vantage Market
Research | 16-Jan-2025
FAQ
Frequently Asked Question
What is the global demand for Parkinson’s Disease Treatment in terms of revenue?
-
The global Parkinson’s Disease Treatment valued at USD 6.67 Billion in 2024 and is expected to reach USD 19.24 Billion in 2035 growing at a CAGR of 10.1%.
Which are the prominent players in the market?
-
The prominent players in the market are Cerevel Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc. (GSK), AbbVie Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals Inc..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 10.1% between 2025 and 2035.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Parkinson’s Disease Treatment include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Parkinson’s Disease Treatment in 2024.
